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ABSTRACT 9 
A range of 17 ternary formulations of itraconazole (ITZ), HPMCP and Soluplus have been 10 
manufactured using spray drying. These amorphous solid dispersions (ASDs) were very stable 11 
against crystallisation and ITZ was found to be amorphous in all formulations after one year at 12 
40 oC / 75% RH. A number of solid state analytical techniques including PXRD, DSC, small angle 13 
X-ray scattering, FTIR and solid state NMR were used to characterise the physicochemical 14 
properties of the ASDs following processing and storage and to assess any interactions between 15 
components. Microtrac laser scattering analysis revealed a relationship between polymer levels and 16 
particle size distribution (PSD). Dissolution studies indicated that higher Soluplus content in the 17 
formulation resulted in higher concentrations of ITZ in acidic media. 18 
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1. INTRODUCTION 21 
Despite the disparity between the significant research efforts in the past four decades and the 22 
number of successfully introduced systems into the market, the preparation of amorphous solid 23 
dispersions (ASDs) still holds a key position among the various formulation approaches intended to 24 
improve the dissolution rate of BCS II compounds (Guns et al., 2011). With higher Gibbs free 25 
energy than their crystalline counterparts, amorphous systems possess greater apparent aqueous 26 
solubility but are thermodynamically unstable, exhibiting a tendency towards spontaneous 27 
crystallisation. To enhance the physical stability of pure amorphous active pharmaceutical 28 
ingredient (API) a carrier, often an amorphous polymer, can be used to provide practical physical 29 
stability to the amorphous systems (Vasconcelos et al., 2007).  The inclusion of an additional 30 
polymer, however, selected based on its physiochemical properties, enables the design of more 31 
sophisticated delivery strategies with the amorphous drug in solid dispersion exhibiting a reduced 32 
particle size and lower thermodynamic barrier to dissolution (Verma and Rudraraju, 2014). 33 
Several formulation approaches and manufacturing techniques to prepare ASDs containing 34 
poorly water soluble APIs have been introduced, for example spray drying (SD), hot melt extrusion 35 
(HME) and freeze drying (FD) (Douglas et al., 2015)(Kumar et al., 2014) (Cerdeira et al., 2013). 36 
Among these, spray drying is being more and more utilised to develop solid molecular dispersions 37 
of poorly soluble drugs (Hengsawas Surasarang et al., 2016)(Sawicki et al., 2016) resulting in 38 
enhanced solubility and the development of sustained and targeted drug delivery systems.  39 
Physicochemically, itraconazole (ITZ) can be categorised as a weak base, BCS class II 40 
compound with very poor water solubility of 1 ng/mL at neutral pH. The first oral dosage form of 41 
itraconazole was manufactured using a solid solution method in which the solvent based drug-42 
polymer mixture was sprayed onto an inert sugar sphere in a closed Wurster process (Peeters et al., 43 
2002). However, where most ASDs in the literature have been binary systems, comprising of drug 44 
and excipient polymer, reports have suggested that ternary ASD systems can have a stability 45 
advantage over binary (Six et al., 2004). 46 
The aim of this project was to generate an optimised formulation comprising amorphous 47 
itraconazole and two excipient polymers in which the itraconazole was stable in the amorphous 48 
form over an extended period and which exhibited the capability to produce and maintain a 49 
supersaturation of itraconazole in acidic media.  50 
2. MATERIALS AND METHODS 51 
2.1 Materials 52 
Itraconazole (>99%) was purchased from Xi'an Lyphar Biotech Ltd. Accurate analytical standard 53 
of itraconazole (99.8%) for HPLC calibration was purchased from Sigma Aldrich. Polymers 54 
Soluplus and HPMCP HP-55 (HPMCP) were donated by BASF and Shin Etsu respectively. 55 
Solvents and chemicals were purchased from Sigma-Aldrich and were of HPLC and reagent grade. 56 
2.2 Pre-formulation polymer and solvent selection test 57 
In a typical experiment dichloromethane-methanol (1:1 v/v, 5 mL) was added to itraconazole 58 
(30 mg), Soluplus (30 mg) and HPMCP (40 mg) followed by vortex mixing (5 min) and visual 59 
inspection. 60 
2.3 Design of Experiments (DoE) 61 
Design-Expert 9.0.6 software (Stat-Ease, Minneapolis) was utilised to generate a variety of 17 62 
optimised formulations containing drug loads of 10 - 30% (Figure 2 and Table 1). DoE has been 63 
employed to provide a methodical way of choosing the drug-polymer ratios.  64 
2.4 Spray drying 65 
A Büchi B-290 mini spray dryer was set up with a B-295 inert loop to enable the use of organic 66 
solvents and was connected to a condenser maintained at -20 °C and a high efficiency cyclone. A 67 
0.7 mm 2-fluid pneumatic nozzle was fitted and the API - polymer solution was sprayed under a 68 
stream of nitrogen. Atomising nitrogen flowrate was ~473 L/h and the aspirator for the drying 69 
nitrogen was set to 100% (35 m3/h). The solution (0.5% w/v) of ITZ, Soluplus and HPMCP in 70 
dichloromethane - methanol (500 mL, 1:1 v/v) was pumped at 4 mL/min. Inlet temperature was set 71 
at 66 oC producing an outlet temperature of 40 ± 3 oC. All variables affecting the outcome of a 72 
spray drying experiment such as outlet temperature, solution concentration, aspirator rate, pumping 73 
speed were fixed between runs so that only formulation composition was varied. Powdered product 74 
was immediately analysed by PXRD and transferred to stability trial. 75 
2.5 Stability studies 76 
Ternary dispersions of ITZ were stored at (i) 20 oC / 0% RH and (ii) 40 oC / 75% RH using 77 
Amebis® stability pods and cabinets. The samples in the pods were monitored wirelessly by 78 
Amebis® software to ensure that temperature / relative humidity settings did not vary over time. 79 
Samples were removed for analysis at day 0, one month, three months and one year by PXRD. 80 
Other techniques mentioned directly below ascertained the stability of the powders after one year at 81 
these conditions. 82 
2.6 Powder X-ray diffraction (PXRD) and Small-angle X-ray scattering (SAXS) 83 
A PANalytical Empyrean X-ray diffractometer attached to a computer running High Score Plus 84 
was used to collect and process X-ray data. Diffraction patterns were collected in-situ, by spinning 85 
powders on zero background discs within the X-ray beam. The radiation was generated by Cu filter 86 
at 40 kV and 40 mA. Data was collected over the 2θ range of 5-50o, with a step size of 0.026o and a 87 
step time of 56 s. Small-angle X-ray scattering (SAXS) was performed on a Philips XPERT Pro 88 
MPD diffractometer. Powders were spun on zero background discs within an X-ray beam generated 89 
by Cu filter at 40 kV and 40 mZ. Data was collected over the 2θ range of 1-10o, with a step size of 90 
0.017o and a step time of 40 s. 91 
2.7 Differential scanning calorimetry (DSC) 92 
DSC studies were conducted on a PerkinElmer DSC 8500 equipped with a refrigerated cooling 93 
accessory (PerkinElmer, Workingham) using helium (30 mL/min) as the purge gas. The instrument 94 
was calibrated at heating rates of 100 and 200 °C / min using high purity indium and zinc to 95 
standardise the temperature and heat flow signals. Samples (2.0 − 5.0 mg) were weighed and placed 96 
in crimped DSC pans, then ramped from 0 - 180 °C at 100 °C / min to check for crystallinity or 97 
200 °C / min to study the glass transition regions. Analysis was carried out using PE Pyris Thermal 98 
Analysis software, version 10.1 and any numerical values reported are the average ± SD of three 99 
independently prepared samples. 100 
2.8 Solid state nuclear magnetic resonance spectroscopy (ssNMR) 101 
13C solid state NMR spectra were recorded on a Bruker Avance III instrument operating with a 4 102 
mm probe operating in double resonance mode. Samples were packed into 4 mm zirconia rotors and 103 
spun at 8 kHz at a magnetic field strength of 400.14 MHz for 1H and 100.61 MHz for 13C. The 104 
pulse sequence for 13C acquisition employed ramped cross-polarisation (CP) with a 70-100% ramp 105 
on the 1H channel and high power 1H decoupling with a SPINAL64 scheme. Magic angle spinning 106 
(MAS) was performed at 8000 Hz for all experiments and the 1H 90o pulse width was 3.1 µs. The 107 
CP contact time was 0.5 - 4 ms with recycle delays of 3 - 6 s depending on the T1 of the sample. A 108 
total of 1024 scans were averaged for each spectrum shown. 1H T1 (spin-lattice relaxation) were 109 
made using a 13C-detected saturation recovery pulse sequence, with 13 recovery delay slices 110 
ranging from 0.1 to 100 s. The magnetic field was adjusted such that the methylene peak of 111 
adamantane resonated at 38.48 ppm. Peak width was adjusted by setting the middle and fifth peaks 112 
of KBr to 128.29 and 134.14 respectively. Data was analysed using Bruker TopSpin 3.5 software. 113 
2.9 Attenuated Total Reflection Fourier Transform Infra-red Spectroscopy 114 
Molecular interactions between ITZ and the polymers were characterised using an FT-IR 115 
spectrometer equipped with a universal attenuated total reflection (ATR) accessory (PerkinElmer 116 
Spectrum 100). A small amount of each sample was placed in the ATR cell, and pressure was 117 
applied with a pressure arm. Scans were collected in the range of 4,000–650 cm−1 using the 118 
Spectrum software package (PerkinElmer, MA, USA). 119 
2.10 Scanning electron microscopy (SEM) 120 
Drug polymer formulations were attached to double sided carbon tape and sputter coated with a 121 
thin layer of gold followed by imaging using a Joel CarryScope JCM-5700 scanning electron 122 
microscope. Micrographs were recorded at 500, 2000 and 5000 times magnification, using a beam 123 
acceleration voltage of 5 kV, a spot size of 40 and a working distance of 12. 124 
2.11 Supersaturated in vitro dissolution studies 125 
The dissolution studies were carried out under non-sink conditions in glass bottles (100 mL) 126 
equipped with magnetic stirring bars (30 mm) rotating at 100 rpm. Glass vessels were charged with 127 
dissolution media (0.1 N HCl, 75 mL) at 37 ± 0.5 oC. A quantity of formulation or drug equivalent 128 
to 37.5 ± 1 mg of ITZ (375 µg/mL, approximately 100 times the 0.1N equilibrium concentration 129 
solubility of 4 µg/mL), was weighed into a glass vial. The powder was pre-wetted with 2 mL of pre-130 
heated HCl media using a Pasteur pipette and quantitatively washed into the dissolution media. 131 
During testing, samples (1.0 mL) were removed by syringe at 1, 2, 3, 4, 5, 6 and 24 h (without 132 
replacement) and immediately filtered (0.45 µm PTFE syringe filters) into HPLC vials already 133 
containing an equal volume of mobile phase (to minimise adsorption or crystallisation). 134 
Immediately after the second sample (2h), tribasic sodium phosphate (0.2M, 25 ± 1 mL) was added 135 
to give a neutral pH of 6.8 ± 0.1 using a calibrated pH meter, in accordance with USP guidelines for 136 
extended release dosage forms (Method A). 137 
2.12 High performance liquid chromatography (HPLC) 138 
Dissolution samples were analysed using an Agilent (Agilent, Little Island, Cork) 1260 Infinity 139 
II high performance liquid chromatography system, comprising of quaternary pump G1311B, diode 140 
array detector G1315D set at wavelength 263 nm, autosampler G1329B and thermostated column 141 
compartment G1316A set at 25.0 oC. The system was operated under isocratic flow at 1 mL/min 142 
using a mobile phase of acetonitrile:water:diethanolamine (69.95/30/0.05) equipped with a 143 
Phenomenex Luna 5 µm C18(2) 100 Å 150 mm x 4.6 mm (Phenomenex, Macclesfield, Cheshire) 144 
RP-HPLC column. Samples collected from the dissolution assay were injected in volumes of 20 µL. 145 
Data were collected and analysed using Aglilent ChemStation software version C.01.07. Standards 146 
of ITZ (99.8% purity) were prepared in methanol from a stock solution of 1 mg/mL to quantify the 147 
levels of drug in the samples.  148 
2.13 Particle size distribution (PSD) 149 
A Microtrac S3500 series particle size analyser with tri-laser technology (Microtrac Inc., 150 
Montgomeryville, PA) was used to determine the particle size distribution of the samples. Dry 151 
measurements were carried out using air as the medium to convey the sample to the measuring cell. 152 
3. RESULTS AND DISCUSSION 153 
3.1 Polymer selection 154 
The system was designed to contain two polymers with differing solubilities in aqueous media, 155 
similar to the system previously reported by Six and co-workers (Six et al., 2004). The dissolution 156 
of itraconazole is typically carried out in acidic media so one enteric and one non-enteric polymer 157 
were selected. Based on miniaturised solvent casting studies previously carried out in this group, 158 
Soluplus and HPMCP were selected (Davis et al., 2015). Soluplus is amphiphilic in nature and 159 
aqueous-soluble while HPMCP is insoluble in acidic aqueous conditions. Furthermore, Soluplus 160 
would be expected to exhibit a greater wettability and hydrophilicity than HPMCP (Zhong et al., 161 
2016). The functional group chemistry of Soluplus includes H-bond acceptors caprolactam and 162 
acetate whilst the PEGylated region improves aqueous solubility (Figure 1). HPMCP contains 163 
phthalate which contributes to lowering the overall aqueous solubility, but imparts hydrogen-bond 164 
donation capability. Ternary formulation design is displayed in Figure 2. 165 
This work involved spray drying and was run concurrently with an hot melt extrusion project in 166 
our group also studying ternary ITZ-Soluplus-HPMCP blends, so it was important that the selected 167 
polymers were suitable for both spray drying and hot melt extrusion. One of the advantages of spray 168 
drying is the ease with which excipients with differing properties can be incorporated, provided that 169 
a mutually appropriate solvent can be found. Hot melt extrusion, however, relies on excipients 170 
having suitable thermoplastic properties. Soluplus is suitable for processing by both hot melt 171 
extrusion and solvent evaporation (spray drying) methods while HPMCP, as a cellulosic polymer 172 
with a high Tg, can be difficult to extrude without the use of plasticisers (Karandikar et al., 2015). 173 
HPMCP also has a proven record as a suitable polymer for the formulation of ITZ (Parikh et al., 174 
2015). Lozanoc® (Mayne Pharma, Australia) has recently come to market in Australia and the EU 175 
and is a 40% dispersion of ITZ on 60% HPMCP HP-50. In our studies of these systems, we have 176 
found that the inclusion of Soluplus with HPMCP has led to ease of processing by hot melt 177 
extrusion and contributes to higher drug concentrations in acidic media. 178 
3.2 Spray Drying 179 
A solubility screening step was introduced prior to spray drying to ensure that the three 180 
components were in solution to aid production of a homogenous product. After a range of 181 
permutations, dichloromethane-methanol (1:1) was selected as the solvent as it was capable of 182 
completely dissolving all three components at the required loading. The spray dried product was a 183 
white, fluffy powder which, following inspection using SEM, was shown to be comprised of 184 
particles with a collapsed or dimpled shape. The development of particles of this nature with an 185 
uneven surface has been associated with the spray drying of solutions with a Peclet number greater 186 
than 1 which causes regions of high viscosity to develop on the surface of the particles during 187 
drying and which is typical of solutions containing polymers (Vehring, 2008)(Bittner and Kissel, 188 
1999). The resultant powders from each run were also analysed by Microtrac particle size analysis. 189 
The cumulative diameters of the powdered products ranged from D10 0.681 µm (ASD 8) to 0.782 190 
µm (ASD 3); D50 1.51 µm (ASD 8) to 2.37 µm (ASD 3) and D95 13.5 µm (ASD 11) to 244.4 µm 191 
(ASD 17). In general the majority of the particles fell into the size range 1-10 µm and the presence 192 
of particles a number of orders larger than this was attributed to particle agglomeration during 193 
drying and storage.  194 
3.3 PXRD and SAXS 195 
Each of the produced spray dried formulations were immediately analysed by PXRD on Day 0. 196 
The powders were then filled into vials and transferred to a desiccator at 20 oC / 0% RH and to 197 
Amebis® stability pods in controlled ovens at 40 oC / 75% RH. Over the following year, samples 198 
were removed for PXRD analysis at weeks 2, 4, 8, 12, 16, 48 and 52. The test is used to mimic 199 
shelf-life storage stability of pharmaceutical formulations. For all samples at each time point no 200 
Bragg peaks were detected and from this it was concluded that all formulations were PXRD 201 
amorphous (Figure 3). The sensitivity of the PXRD method was confirmed separately with a spray 202 
dried powdered formulation of itraconazole-HPMCAS-Soluplus (20:40:40) which was PXRD 203 
amorphous at day 0, but from which the characteristic Braggs peaks of ITZ could be observed 204 
following four weeks of storage.  205 
SAXS was performed after one year of storage following a recent report of liquid crystalline 206 
phases of itraconazole from Tajber and co-workers (Mugheirbi and Tajber, 2015). The technique 207 
was used to detect any short range order indicative of a liquid crystalline phase which might not be 208 
detected by standard PXRD. None of the formulations showed any trace of this short range liquid 209 
crystalline character. 210 
3.4 DSC 211 
Through the use of the Perkin Elmer DSC8500 it was possible to explore the use of much faster 212 
heating rates than are used during standard DSC. In increasing heating rate the sensitivity of the 213 
DSC is also increased and thus smaller transitional changes can be detected beyond the threshold of 214 
instrumental noise (Craig and Reading, 2006). This analysis method was therefore utilised as one 215 
which might give better sensitivity to any crystallinity contained in the formulations. All of the 216 
samples from the stability study were tested i.e. from the desiccator and from the Amebis® system 217 
at 40 oC / 75% RH and even using this increased sensitivity analysis method the absence of any 218 
melt exotherm around the melting point of the API (168.7 ± 0.3 °C measured using a heating rate of 219 
100 °C/min) was confirmed (Figure 4). 220 
The difficulty in measuring the glass transition event in celluloses is well known (McPhillips et 221 
al., 1999) so having the capability to probe the thermal glass transition region using increased 222 
heating rates was advantageous. A disadvantage associated with increasing the heating rate in DSC 223 
is the decreased resolution of thermal events. Two peaks which may be fully resolved at a slower 224 
heating rate can merge together when heated more quickly. For this reason 100 °C / min was 225 
determined to be the optimum heating rate for the detection of crystalline material around the 226 
melting point of the API, however to better detect the weak Tg of HPMCP 200 °C / min was used. 227 
At this heating rate the measured Tg of ITZ, Soluplus and HPMCP is 59.0 ± 0.9, 82.1 ± 2.2 and 228 
147.6 ± 1.5 oC (all n = 3) respectively. Van den Mooter and co-workers claimed that the anti-229 
plasticising effect of the polymer, rather than intermolecular interactions, was the only relevant 230 
factor (Van den Mooter et al., 2001) contributing to system stability. HPMCP has a greater 231 
stabilising influence on ITZ than Soluplus either through its propensity to hydrogen bond with ITZ 232 
or due its higher Tg. 233 
Analysis of the glass transition region of the DSC thermograms indicated that two glass 234 
transitions were present in the samples (Table 1). A single glass transition area is often desired in an 235 
ASD as it indicates that the system is completely homogenous and that the components have been 236 
well mixed during processing (Huang and Dai, 2014). In practice, it was observed that each 237 
formulation had two glass transitions, one just below or around the glass transition value of 238 
Soluplus and one just below that of HPMCP, corresponding to HPMCP-rich and Soluplus-rich 239 
amorphous drug phases. None of the measured Tgs corresponded to the value of pure itraconazole 240 
so it could be concluded that rather than the drug separating out from the polymer, that the drug had 241 
remained associated with the two polymers, but that the polymers themselves had either partially or 242 
fully dissociated from each other. The interactions between drug and polymers in a ternary system 243 
are extremely complex. Due to the size of the polymers and the large number and variety of 244 
functional groups a huge number of intermolecular association permutations are possible. Drug-245 
drug, drug-polymer 1, drug-polymer 2, polymer 1-polymer-1, polymer 1-polymer 2, polymer 2-246 
polymer 2 interactions are all possible, even before the complexities of water vapour uptake are 247 
considered.  248 
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The Couchman-Karasz equation for ternary systems (Equation 1) can be used to predict the 250 
value of the glass transition temperature(s) of such systems (Levine, 2002). The equation is based 251 
on classical thermodynamics theory with an assumption that the system is purely conformational 252 
where 𝑥𝑖  refers to the mass fraction of component i, ΔCpi is the change in heat capacity of 253 
component i between its liquid-like and glassy states. For polymer blends of three components the 254 
subscript 1 refers to HPMCP, subscript 2 to Soluplus and 3 refers to the component of lowest Tg, in 255 
this case ITZ. 256 
Due to the complexity of the ternary systems, the assumption of ideal mixing incorporated into 257 
the Couchman-Karasz equation may not be applicable; nevertheless, the values produced from the 258 
equation generally fell near to the halfway point between the two present values. The forces behind 259 
such a separation are unclear, but may be due to polarity and conformational flexibility issues. In 260 
any case, the stability against crystallisation of the ternary systems was excellent and the solubility 261 
was greatly increased compared to the crystalline drug and these outcomes were considered to be 262 
the most important, although a single homogenous formulation would be preferred. 263 
3.5 DOE RESULTS 264 
The factors measured were the weight percents (% w/w) of formulation ingredients; factor A: 265 
ITZ, factor B: Soluplus, and factor C: HPMCP and their percent amounts sum to 100%.  The limits 266 
for the percent amounts of ITZ 10% ≤ A ≤ 30% and Soluplus and HPMCP 30% ≤ B/C ≤ 60%.  Two 267 
responses were recorded, namely the value of the two measured Tgs (Tg1 and Tg2 in Table 1), and 268 
analysis of data was carried out using two separate ANOVA; one for each response). A graphical 269 
representation of the results for the two models is shown in Figure 2.  270 
On the basis of comparison of statistical indices for model adequacy, a Linear Mixture model 271 
was selected for both responses as shown in Eq (2) and Eq (3) below: 272 
Final equation for Tg1 in terms of real components 273 
Tg1=+65.48980×ITZ+97.96599×Soluplus+68.48028×HPMCP    [2] 274 
Final equation for Tg2 in terms of real components 275 
Tg2=+60.62902×ITZ+115.66711×Soluplus+189.72426×HPMCP   [3] 276 
Values of "Prob > F" less than 0.0500 indicate model terms are significant. Model 1 exhibited a 277 
model F-value of 3.1 and a "Prob > F" of 0.0411 while the similar values for model 2 were 26.78 278 
and 0.0001, implying that both models are significant. There is only a 4.11% or 0.01% (model 1 and 279 
2 respectively) chance that F-values this large could occur due to noise. In both cases A, B and C 280 
terms are significant model terms. 281 
From Figure 2a is it observed that Tg1 increases with increasing Soluplus content. This 282 
observation is in agreement with the characterisation of these formulations as containing a 283 
Soluplus-rich and an HPMCP-rich amorphous phase. Therefore as the amount of Soluplus in the 284 
formulation increases, the ratio of Soluplus to ITZ in the Soluplus-rich phase increases, thus causing 285 
an increased overall Tg due to the higher Tg of the polymer in comparison to the API. From Figure 286 
2b it is observed that as HPMCP content increases, Tg2 is increased. There is, however, a difference 287 
in the gradient of the contour lines between the two models. For model 1 ITZ and HPMCP are 288 
given similar weighting in the calculation of Tg1, with the contour lines orthogonal to the Soluplus 289 
axis. Conversely for model 2, the contour lines are shifted toward Soluplus, suggesting a change in 290 
the contribution of Soluplus to Tg2 depending on HPMCP content and a possible limit to the 291 
miscibility of Soluplus in the ITZ-HPMCP system.  292 
3.6 FTIR and ssNMR 293 
The FTIR spectra for the formulations prepared in this study and the individual components are 294 
presented in Figure 5. At 898 cm-1 a peak was observed in the crystalline sample of ITZ only. The 295 
peak was not present in the amorphous sample of ITZ (prepared by melt quench), in any of the 296 
formulations or the polymers. 898 cm-1 is most likely due to an aromatic C-H out-of-plane bending 297 
vibration. ATR-FTIR represents a rapid test method for qualitatively determining the presence or 298 
absence of crystalline ITZ with minimal sample preparation time. 299 
The impact of hydrogen-bonding in amorphous dispersion stability has been well documented 300 
(Vasanthavada et al., 2005). ITZ cannot self-associate through H-bonding, as it contains only donor 301 
functional groups, however it can H-bond to HPMCP and may form other associations with 302 
Soluplus. Soluplus cannot self-associate as it contains only acceptors, but can H-bond with 303 
HPMCP. HPMCP can associate with itself, the drug and Soluplus as it contains both acceptors and 304 
donors. The phthalate functional group is able to associate favourably with the ITZ aromatic rings 305 
through π-π interactions. Conformational flexibility of the components will be limited by rotational 306 
degrees of freedom around individual bonds reducing the number of possible interactions. For 307 
instance, HPMCP will be limited in flexibility due to the preferred orientation of the glucopyranose 308 
rings.  309 
Solid state NMR spectra were recorded of ASD 16 (containing 30% drug load, 40% Soluplus 310 
and 30% HPMCP) after one year of storage in a desiccator (Figure 6). The data compared well with 311 
that previously reported (Van Eerdenbrugh et al., 2009)(Song et al., 2015). Broadening of the peaks 312 
in ASD 16 relative to crystalline ITZ indicated that the drug was in the amorphous form. ssNMR 313 
also provides additional structural information confirming that the drug was also chemically intact 314 
and had not oxidised or otherwise degraded. 315 
3.7 Dissolution studies 316 
HPLC analysis was performed rather than UV assay to ensure that absorbance was due to analyte 317 
(ITZ) rather than impurities or polymer (e.g. phthalate groups). The retention time of ITZ was 318 
approximately 9.3 min with consistent reproducibility and no unexplained peaks or baseline drift 319 
were encountered. All analytical tests maintained system suitability limits for linearity from 0.100 320 
to 100 µg/mL (r2 ≥ 0.999) and reproducibility of replicate injections (% RSD < 0.3%). Sharp single 321 
peaks at expected Rf values confirmed lack of chemical or bacterial degradation during the one year 322 
stability test. The method was based on that previously reported by DiNunzio (DiNunzio et al., 323 
2008). Diethanolamine was added to the mobile to ensure that only deprotonated ITZ (pKa = 3.7) 324 
was present. The limit of detection of was 100 ng/mL. 325 
Dissolution studies were operated under supersaturated, non-sink, in vitro conditions using USP 326 
II method for enteric coated formulations adapted to use a magnetic stirring bar (DiNunzio et al., 327 
2008). The relative dissolution ability of the 17 blends and relationship to the formulation was of 328 
interest. Data for the highest, middle and lowest concentrations is displayed in Figure 7. 329 
Formulation composition and concentration values are displayed in Table 1 and Figure 8. A 330 
comparison of formulation, dissolution and particle size reveals that formulations richer in Soluplus 331 
generally had a lower D50 particle size distribution and a higher solubility. Formulations richer in 332 
HPMCP generally had higher D50 particle size distribution and had lower solubility (Figure 9). The 333 
reason for the larger PSD is most likely because HPMCP has a much greater effect on viscosity 334 
than Soluplus or ITZ. When viscosity is higher droplet formation is more difficult so larger droplets 335 
are formed (Vehring, 2008). The most favourable concentrations after 2 h were from formulations 336 
containing the following component ranges: 10-20% ITZ, 37.5-50% Soluplus and 35-45% HPMCP.  337 
4. CONCLUSIONS 338 
It has been shown that a compositional range of ternary ASDs of ITZ, HPMCP and Soluplus are 339 
extremely stable, remaining amorphous for one year at 40 oC and 75% RH, as confirmed by a range 340 
of techniques; PXRD, SAXS, DSC, FTIR and ssNMR. The formulation with the highest Soluplus 341 
content (60% w/w) and lowest drug content (10% w/w) maintained a homogeneous single 342 
amorphous phase over one year while all others were shown to contain Soluplus-rich and HPMCP-343 
rich phases. Following spray drying those formulations with greater Soluplus content generally had 344 
lower particle size distributions than those containing more HPMCP. Similarly, formulations with 345 
higher Soluplus levels generally exhibited a greater initial rate and extent of dissolution than those 346 
with higher HPMCP content. 347 
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Figure 1: Chemical structures of itraconazole (A), Soluplus (B) and HPMCP (C) 434 
 435 
 436 
 437 
Figure 2: A mixture (user-defined) design space with red dots indicating the 17 formulations. 438 
Circled point corresponds to a composition of 0.1 ITZ: 0.6 Soluplus: 0.3 HPMCP (Run 2 in Table 439 
1). Plot fill colour indicates (a) Tg1 and (b) Tg2 value for the given formulation composition. Blue 440 
dotted arrows have been added as a reading aid for the three axes. 441 
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ASD 1 10 45 45 78.0 142.3 165 
ASD 2 10 60 30 87.8 - 182 
ASD 3 10 30 60 74.4 147.1 131 
ASD 4 15 42.5 42.5 90.1 140.8 193 
ASD 5 15 50 35 78.7 130.3 172 
ASD 6 15 35 50 81.5 145.7 168 
ASD 7 20 40 40 81.8 139.4 203 
ASD 8 20 50 30 81.5 124.1 151 
ASD 9 20 30 50 73.2 146.1 141 
ASD 10 20 35 45 80.4 142.2 142 
ASD 11 20 45 35 76.9 128.8 179 
ASD 12 25 37.5 37.5 80.9 135.5 171 
ASD 13 25 40 35 81.9 128.4 156 
ASD 14 25 35 40 73.5 130.6 152 
ASD 15 30 35 35 76.8 115.4 158 
ASD 16 30 40 30 77.7 119.7 127 
ASD 17 30 30 40 79.4 131.4 145 
Table 1: ASD formulation code, composition (% w/w), values of glass transition temperatures (oC) and drug 443 
concentration (µg / mL) after 2 h in acidic dissolution media. 444 
 445 
Figure 3: PXRD traces from analysis of ASD 14 (ITZ 25%, Soluplus 35% & HPMCP 40%) showing amorphous halo at 446 
Day 0 and weeks 2 to 50. Other ASD gave similar PXRD results. 447 
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Figure 4: DSC thermograms of ASD 1 - 17 following storage at 40 
o
C / 75% RH for 1 year. Crystalline ITZ is included, 449 
melting from 161 - 182 
o
C. The melt peak did not appear in any of the 17 formulae, confirming that the amorphous 450 
form is very stable. 451 
 452 
Figure 5: ATR-FTIR spectra of crystalline ITZ, amorphous ITZ, Soluplus, HPMCP and ASD 1 – 17. The peak at 898 453 
cm
-1
 was attributed to an aromatic C-H out-of-plane bending vibration and was detected only in crystalline ITZ, but not 454 
in ASD 1 – 17, indicating that the drug was amorphous in every formulation.455 
 456 
Figure 6: 
13
C-CPMAS ssNMR spectra of Soluplus, HPMCP, crystalline ITZ and ASD 16 (after 1 year of storage). 457 
Broadened ITZ peaks demonstrated that the drug was physically amorphous and chemically intact 458 
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Figure 7: Non-sink, supersaturated, in vitro dissolution studies using the FDA method recommended for enteric 460 
formulations. ASD 7, 15 and 16 represented the high, middle and low values within the 17 formulations and crystalline 461 
ITZ was included for comparison. Samples were removed at 1, 2, 3, 4, 5, 6 and 24 h and analysed directly by HPLC. 462 
Crystalline ITZ released 4 µg / mL after 1 h, but was below the limit of detection (100 ng / mL) post neutralisation, due 463 
to precipitation. Release of drug post neutralisation was low but higher values were found in formulations with higher 464 
levels of HPMCP. 465 
 466 
Figure 8: Concentration values for ITZ ASD 1-17 and crystalline ITZ following 2 h dissolution in acidic media with 467 
non-sink conditions. Each ASD achieved a greatly superior concentration to crystalline ITZ, up to 50 times higher in the 468 
best case. The concentration values varied according to formulation composition with lowest and highest values of 127 469 
(ASD 16) and 203 µg / mL ITZ (ASD 7) respectively 470 
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 472 
Figure 9: The relationship between particle size distribution (PSD) D50 values and formulation composition by quantity 473 
of HPMCP and Soluplus used (expressed as mg of polymer out of a 2.500 g formulation total mass). An increase in 474 
HPMCP concentration generally led to higher D50 values whilst an increase in Soluplus D50 values generally led to 475 
lower D50 values.  476 
